敬老院1号 管理员Lv12 关闭了本次求助。
说明 求助违规(查看求助规则):该文献不存在全文(会议摘要、poster、视频等)。以后求助的时候,留意把标题和DO信息复制完整。【积分已退回】
龚迎梦 求助人 Lv3 进行了留言
@wanci 2021 ESMO的摘要,链接为: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-and-safety-of-pemigatinib-in-chinese-patients-with-unresectable-advanced-recurrent-or-metastatic-intrahepatic-cholangiocarcinoma-with-fg 谢谢~ 回复
@wanci 2021 ESMO的摘要,链接为: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-and-safety-of-pemigatinib-in-chinese-patients-with-unresectable-advanced-recurrent-or-metastatic-intrahepatic-cholangiocarcinoma-with-fg
wanci Lv12 进行了留言
2021 ESMO的摘要,链接为: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-and-safety-of-pemigatinib-in-chinese-patients-with-unresectable-advanced-recurrent-or-metastatic-intrahepatic-cholangiocarcinoma-with-fg 回复
zhencheng Lv4 撤回了 zhencheng 上传的文件。
说明 上传错了
zhencheng Lv4 上传了文件
已撤回 ome-11-9-2877.pdf (2.94 MB) 回复
龚迎梦 求助人 Lv3 发起了本次求助